Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection (ANRS 12100 HEPADAK-2)
Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection
Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Terminated
poor patient recrutment
Other terminated trials from French National Agency for Research on AIDS and Viral Hepatitis
- Chronic Hepatitis C · Phase PHASE3 · Jul 2012
- HBe Negative Chronic Hepatitis B · Phase PHASE3 · Dec 2008
- HIV Infections · Phase PHASE1/PHASE2 · Oct 2008
- Hepatitis C, Chronic · Phase PHASE3 · Dec 2006
- HIV Infections · Phase PHASE2/PHASE3 · Mar 2006
See all terminations from French National Agency for Research on AIDS and Viral Hepatitis
A PHASE3 clinical study on Hepatitis B, this trial is terminated or withdrawn. The trial is conducted by French National Agency for Research on AIDS and Viral Hepatitis and has accumulated 6 data snapshots since 2005. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Oct 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Aug 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- French National Agency for Research on AIDS and Viral Hepatitis
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .